Sigma Planning Corp Buys 11,000 Shares of Halozyme Therapeutics, Inc. $HALO

Sigma Planning Corp boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 114.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 20,592 shares of the biopharmaceutical company’s stock after buying an additional 11,000 shares during the quarter. Sigma Planning Corp’s holdings in Halozyme Therapeutics were worth $1,331,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of HALO. Hillsdale Investment Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 2.4% in the 1st quarter. Hillsdale Investment Management Inc. now owns 110,050 shares of the biopharmaceutical company’s stock worth $7,113,000 after acquiring an additional 2,600 shares during the last quarter. State of Michigan Retirement System grew its holdings in Halozyme Therapeutics by 1.8% during the 1st quarter. State of Michigan Retirement System now owns 28,338 shares of the biopharmaceutical company’s stock valued at $1,831,000 after purchasing an additional 500 shares during the last quarter. Principal Financial Group Inc. raised its position in Halozyme Therapeutics by 4.9% in the 1st quarter. Principal Financial Group Inc. now owns 264,490 shares of the biopharmaceutical company’s stock worth $17,094,000 after purchasing an additional 12,438 shares during the period. Arbejdsmarkedets Tillaegspension lifted its stake in Halozyme Therapeutics by 8.6% in the first quarter. Arbejdsmarkedets Tillaegspension now owns 408,391 shares of the biopharmaceutical company’s stock worth $26,394,000 after purchasing an additional 32,458 shares during the last quarter. Finally, Diversify Wealth Management LLC lifted its stake in Halozyme Therapeutics by 49.1% in the first quarter. Diversify Wealth Management LLC now owns 31,504 shares of the biopharmaceutical company’s stock worth $1,987,000 after purchasing an additional 10,371 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $55,088,215. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $77.81 on Friday. The company has a 50 day moving average price of $72.03 and a 200-day moving average price of $70.20. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a fifty-two week low of $55.64 and a fifty-two week high of $82.26. The company has a market capitalization of $9.23 billion, a PE ratio of 27.99, a P/E/G ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.